市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Erasca, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
-2.3
| 分析师共识 | -1.5 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -2.25 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 11.69% |
| 机构持股比例 | 84.38% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 4.00 (Stifel, 69.49%) | 购买 |
| 中 | 2.00 (-15.25%) | |
| 低 | 1.00 (B of A Securities, -57.63%) | 卖出 |
| 平均值 | 2.33 (-1.27%) | |
| 总计 | 1 购买, 1 保留, 1 卖出 | |
| 平均价格@调整类型 | 1.83 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 16 Oct 2025 | 4.00 (69.49%) | 购买 | 2.53 |
| B of A Securities | 03 Sep 2025 | 1.00 (-57.63%) | 卖出 | 1.43 |
| Morgan Stanley | 18 Aug 2025 | 2.00 (-15.25%) | 保留 | 1.53 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合